Sanofi agrees to buy U.S. mRNA partner Translate Bio in $3.2 bln deal
The Hindu
Sanofi has agreed to buy U.S. biotech company Translate Bio in a $3.2 billion deal, as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.Sanofi said it would acqui
Sanofi has agreed to buy U.S. biotech company Translate Bio in a $3.2 billion deal, as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race. Sanofi said it would acquire all outstanding shares of Translate Bio for $38.00 per share in cash, representing a total equity value of about $3.2 billion for Translate Bio. The boards of both companies have approved the deal, and the chief executive of Translate Bio and the U.S. company’s largest share holder have backed the takeover offer, Sanofi and Translate Bio said in a joint statement.More Related News